Feasibility, Acceptability and Costs of a Strategy Deploying Multiple First-lines Artemisinin-based Combination Therapies for Uncomplicated Malaria: a Pilot Programme in the Health District of Kaya, Burkina Faso

简要总结

详细描述

主要结局

次要结局

• Average number of monitoring visits performed per annum(Through the MFTs deployment phase: 12 months of duration.)
• Average number of monitoring visits on which health facilities have stock out of mRDTs per annum.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of community resources people with unfavourable opinions to the MFTs pilot program.(From the formative phase to the end of drugs deployment: 18 months duration.)
• Average number of monitoring visits on which drugs stores have stock out of any dose of study ACTs per annum.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of febrile episode seen at HFL within 24 hours with negative diagnostic test who did not received any antimalarial.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of febrile episode seen at HFL within 24 hours with negative diagnostic test who received an ACT.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of febrile episode seen at health facility level.(Through the MFTs deployment phase: 12 months of duration)
• Proportion of febrile episodes treated with ACTs adhering to ACT treatment schedule (timing and doses) by HWs according to MFTs strategy(During MFTs deployment phase at peak malaria season: 6 months of duration.)
• Cost per additional inappropriate antimalarial treatment avoided.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of febrile episode seen at health facility level (HFL) within 24 hours(Through the MFTs deployment phase: 12 months of duration)
• Proportion of febrile episode seen at HFL within 24 hours and tested for parasitemia.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of febrile episode seen at HFL within 24 hours with positive diagnostic test who were given ACT according to the MFTs strategy(Through the MFTs deployment phase: 12 months of duration.)
• Cost per additional febrile episode receiving prompt treatment or confirmed negative diagnosis(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of uncomplicated fever episodes/malaria seen by HW, tested positive and treated with correct dose of ACT according to MFTs pilot program(From the formative phase to the end of drugs deployment: 18 months duration.)
• Proportion of uncomplicated febrile episode/malaria seen at health facility level before and during the MFTs deployment in the study area.(Through the MFTs deployment phase: 12 months of duration.)
• Proportion of community resources people with favourable opinions to the MFTs pilot program.(From the formative phase to the end of drugs deployment: 18 months duration.)
• Incidence of uncomplicated febrile episode/malaria within 4 weeks preceding the surveys(From the formative phase to the end of drugs deployment: 18 months duration.)
• Source of advice or care for those suffering from fever in the last four weeks(From the formative phase to the end of drugs deployment: 18 months duration.)
• The cost per additional febrile episode appropriate managed for malaria with confirmed diagnosis(Through the MFTs deployment phase: 12 months of duration)
• The total cost per capita of intervention (provider perspective)(Through the MFTs deployment phase: 12 months of duration)
• Proportion of episode of uncomplicated fever seen by HWs tested for malaria parasitemia.(From the formative phase to the end of drugs deployment: 18 months duration.)
• Proportion of uncomplicated febrile episodes/malaria seen by HWs provided with advice on danger signs.(From the formative phase to the end of drugs deployment: 18 months duration.)
• Mortality rate related to febrile episode/malaria before and during the pilot MFTs deployment.(From the formative phase to the end of drugs deployment: 18 months duration.)
• Proportion of individuals with fever in the last four weeks for whom advice or treatment was sought(From the formative phase to the end of drugs deployment: 18 months duration.)
• The total cost per capita of intervention (societal perspective)(Through the MFTs deployment phase: 12 months of duration)
• Proportion of febrile episodes treated with ACTs according to MFTs pilot programme by HWs provided with appropriate dosing advice(From the formative phase to the end of drugs deployment: 18 months duration.)
• Proportion of individuals with fever in the last four week who sought treatment at HFL within 24 hours(From the formative phase to the end of drugs deployment: 18 months duration.)
• Cost to the HWs to participate to the MFTs strategy.(Through the MFTs deployment phase: 12 months of duration.)